TNFalpha Blockers Do Not Improve the Hearing Recovery Obtained with Glucocorticoid Therapy in an Autoimmune Experimental Labyrinthitis

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2006 Mar 21

PMID 16547758

Citations 7

Authors

David Lobo

Almudena Trinidad

Jose Ramon Garcia-Berrocal

Jose Maria Verdaguer

Rafael Ramirez-Camacho

Affiliations

Soon will be listed here.

Abstract

The effectiveness of etanercept [tumour necrosis factor-alpha (TNFalpha) blocker] and corticoids in treating immuno-mediated inner ear disease (IMIED) was compared in an animal model of autoimmune labyrinthitis. IMIED is one of the few forms of sensorineural hearing loss that is reversible with proper medical treatment. While the effectiveness and usefulness of immunomodulating agents (corticosteroids) in treating IMIED have been demonstrated, TNFalpha antagonists, which inhibit granuloma formation in rheumatoid arthritis and other autoimmune diseases, have been considered as an alternative therapy. The efficacy of etanercept (anti-TNFalpha) was evaluated in a guinea pig model of experimental autoimmune labyrinthitis in which 25 guinea pigs were divided in a control group, which was used to document the rise in hearing thresholds following immunisation, and two experimental groups, which were treated with steroids (6-methylprednisolone) and anti-TNFalpha (etanercept), respectively, after the immunisation. Comparison of the auditory thresholds obtained by means of auditory brainstem response (ABR) revealed that the auditory thresholds of the two experimental groups were not statistically different (6-methylprednisolone: 41.5 dB, SD: 8.51; etanercept: 37.5 dB, SD: 7.91) and that both compared favourably with that of the control group (60 dB, SD: 7.91) at p=0.001. We therefore conclude that etanercept is as effective as glucocorticoids in an animal model of autoimmune labyrinthitis; however, the potential adverse effects and high price of the former advise against its use as an initial therapy for IMIED.

Citing Articles

Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review.

Creber N, Muzaffar J, Gowrishankar S, Borsetto D, Phillips V, Smith M PLoS One. 2025; 20(2):e0318165.

PMID: 39946404 PMC: 11825040. DOI: 10.1371/journal.pone.0318165.

Audiological Features in Patients with Rheumatoid Arthritis: A Systematic Review.

Chen J, Hsu C, Chen Y, Chen T, Zeng B, Tseng P Int J Mol Sci. 2025; 25(24.

PMID: 39769062 PMC: 11676466. DOI: 10.3390/ijms252413290.

Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review.

Huang K, Lin H, Lin C, Wu P Medicine (Baltimore). 2023; 102(23):e33889.

PMID: 37335659 PMC: 10256420. DOI: 10.1097/MD.0000000000033889.

Cytokines and Inflammation in Meniere Disease.

Frejo L, Lopez-Escamez J Clin Exp Otorhinolaryngol. 2022; 15(1):49-59.

PMID: 35124944 PMC: 8901949. DOI: 10.21053/ceo.2021.00920.

Prophylactic etanercept treatment in cisplatin ototoxicity.

Dasli S, Topdag M, Mutlu A, Kara A, Ozturk M Eur Arch Otorhinolaryngol. 2017; 274(10):3577-3583.

PMID: 28730299 DOI: 10.1007/s00405-017-4677-6.

References

Harris J, Weisman M, Derebery J, Espeland M, Gantz B, Gulya A . Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA. 2003; 290(14):1875-83. DOI: 10.1001/jama.290.14.1875. View

McCabe B . Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979; 88(5 Pt 1):585-9. DOI: 10.1177/000348947908800501. View

Staecker H, Lefebvre P . Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report. Acta Otolaryngol. 2002; 122(6):684-7. DOI: 10.1080/000164802320396402. View

Carvalho G, Lalwani A . The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am J Otol. 1999; 20(1):87-90. View

Rahman M, Poe D, Choi H . Autoimmune vestibulo-cochlear disorders. Curr Opin Rheumatol. 2001; 13(3):184-9. DOI: 10.1097/00002281-200105000-00006. View

Wang X, Truong T, Billings P, Harris J, Keithley E . Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol. 2003; 24(1):52-7. DOI: 10.1097/00129492-200301000-00012. View

Khanna D, Liebling M, Louie J . Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003; 30(8):1864-7. View

Goffe B . Etanercept (Enbrel) -- an update. Skin Therapy Lett. 2005; 9(10):1-4, 9. View

Bansback N, Regier D, Ara R, Brennan A, Shojania K, Esdaile J . An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. Drugs. 2005; 65(4):473-96. DOI: 10.2165/00003495-200565040-00004. View

10.

Rahman M, Poe D, Choi H . Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001; 22(5):619-24. DOI: 10.1097/00129492-200109000-00010. View

11.

Botsios C . Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005; 4(3):162-70. DOI: 10.1016/j.autrev.2004.09.001. View

12.

Ma C, Billings P, Harris J, Keithley E . Characterization of an experimentally induced inner ear immune response. Laryngoscope. 2000; 110(3 Pt 1):451-6. DOI: 10.1097/00005537-200003000-00024. View

13.

Garcia-Berrocal J, Trinidad A, Ramirez-Camacho R, Lobo D, Verdaguer M, Ibanez A . Immunologic work-up study for inner ear disorders: looking for a rational strategy. Acta Otolaryngol. 2005; 125(8):814-8. DOI: 10.1080/00016480510038059. View

14.

Wallis R, Ehlers S . Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005; 34(5 Suppl1):34-8. DOI: 10.1016/j.semarthrit.2005.01.009. View

15.

Satoh H, Firestein G, Billings P, Harris J, Keithley E . Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope. 2002; 112(9):1627-34. DOI: 10.1097/00005537-200209000-00019. View

16.

Garcia-Berrocal J, Ramirez-Camacho R, Trinidad A, Zurita M, de la Fuente R, Lobo D . Controversies and criticisms on designs for experimental autoimmune labyrinthitis. Ann Otol Rhinol Laryngol. 2004; 113(5):404-10. DOI: 10.1177/000348940411300512. View

17.

Garcia Berrocal J, Pinilla Urraca M, Ramirez-Camacho R, Gonzalez Martin F, Lopez Cortijo C . [Inner ear diseases of probable autoimmune origin and its response to steroid treatment]. Acta Otorrinolaringol Esp. 1995; 46(6):416-20. View

18.

Garcia Berrocal J, Ramirez-Camacho R, Zurita M, Arellano B . [Early cellular immune response in experimental labyrinthitis: immunohistochemical study]. Acta Otorrinolaringol Esp. 2001; 51(7):557-61. View

19.

Garcia-Berrocal J, Vicente J, Arellano B, Gonzalez F, Ramirez-Camacho R . [Experimental autoimmune labyrinthitis: evaluation of various models in guinea pigs]. Acta Otorrinolaringol Esp. 1997; 48(1):5-10. View

20.

Goycoolea M . Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol. 2001; 121(4):437-47. DOI: 10.1080/000164801300366552. View